Subscribe

FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer

Web Exclusives - Breast Cancer, FDA Approvals, In the News
Yvette Florio Lane

On May 3, 2019, the US Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Patients should be selected for treatment with this agent based on an FDA-approved companion diagnostic test (Ventana Medical System’s PATHWAY anti-HER-2/neu [4B5] Rabbit Monoclonal Primary Antibody assay or INFORM HER2 Dual ISH DNA Probe Cocktail assay).

This latest approval was based on the phase 3, multicenter, open-label KATHERINE clinical trial of 1486 patients with HER2-positive early breast cancer. Patients were randomized in a 1:1 ratio to ado-trastuzumab emtansine (3.6 mg/kg intravenously every 3 weeks) or trastuzumab (6 mg/kg intravenously every 3 weeks) for 14 cycles. Patients were required to have had neoadjuvant taxane and trastuzumab-based therapy with residual invasive tumor in the breast and/or axillary lymph nodes.

After a median follow-up of 40 months, results showed that treatment with ado-trastuzumab emtansine significantly improved invasive disease-free survival compared with trastuzumab (hazard ratio, 0.50; 95% confidence interval, 0.39-0.64; P <.0001).

The most common adverse reactions (≥25%) associated with ado-trastuzumab in patients with early breast cancer were fatigue, nausea, increased transaminases, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, peripheral neuropathy, and arthralgia.

Ado-trastuzumab emtansine was previously approved by the FDA on February 22, 2013, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.

The recommended dose of ado-trastuzumab emtansine is 3.6 mg/kg given as an intravenous infusion, every 3 weeks (21-day cycle), until disease recurrence or unacceptable toxicity, or a total of 14 cycles for patients with early breast cancer.

Related Items
CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak
Web Exclusives published on March 19, 2020 in Health Policy and Reform, In the News
Sarclisa Newest Treatment Approved by the FDA for Patients with Multiple Myeloma
Web Exclusives published on March 12, 2020 in FDA Approvals
Tazverik First FDA-Approved Drug for Advanced Epithelioid Sarcoma Ineligible for Resection
February 2020 Vol 13, Special Issue published on February 25, 2020 in Drug Updates, FDA Approvals
Ayvakit First Targeted Therapy Approved for Gastrointestinal Stromal Tumors with PDGFRA Mutation
February 2020 Vol 13, Special Issue published on February 25, 2020 in Drug Updates, FDA Approvals
Enhertu, a Dual-Targeted Therapy, Approved for Metastatic HER2-Positive Breast Cancer
February 2020 Vol 13, Special Issue published on February 25, 2020 in Breast Cancer, Drug Updates, FDA Approvals
Last modified: May 14, 2019
Copyright © Engage Healthcare Communications, LLC. All rights reserved.